New shot aims to reverse wasting in cancer patients
NCT ID NCT07519564
First seen Apr 10, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This early-stage study tests an experimental drug called GB18 in cancer patients who are losing weight and muscle (cachexia). The drug is designed to improve appetite and stop weight loss by blocking a specific protein. About 18 to 36 adults with advanced solid tumors will receive multiple doses to check safety and see if it helps them gain weight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CACHEXIA; CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.